Marieke van Son

22 CHAPTER 1 62. Bokhorst LP, Alberts AR, Rannikko A, Valdagni R, Pickles T, Kakehi Y, et al. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Dis- ease Reclassification in Noncompliers. Eur Urol. 2015;68(5):814-21. 63. Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, et al. Extended pelvic lymph node dissection in pros- tate cancer: a 20-year audit in a single center. Annals of oncology : official jour- nal of the European Society for Medical Oncology. 2013;24(6):1459-66. 64. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal Therapy in Metastat- ic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAART- ED Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(11):1080-7. 65. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schroder FH, Sternberg CN, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61(1):11-25. 66. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after an- drogen deprivation therapy: mecha- nisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501-11. 67. Lee RJ, Smith MR. Hormone Therapy for Prostate Cancer. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th ed: Wolters Kluwer: Lippincott Williams & Wilkins; 2011. 68. Kunath F, Jensen K, Pinart M, Kahlmey- er A, Schmidt S, Price CL, et al. Early versus deferred standard androgen suppression therapy for advanced hor- mone-sensitive prostate cancer. The Cochrane database of systematic re- views. 2019;6:CD003506. 69. Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive pros- tate cancer. The Cochrane database of systematic reviews. 2018;10:CD012816. 70. Burdett S, Boeve LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Pros- tate Radiotherapy for Metastatic Hor- mone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Me- ta-analysis. Eur Urol. 2019;76(1):115-24. 71. Spratt DE, Pei X, Yamada J, Kollmei- er MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treat- ed with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):686-92. 72. Ward JF, Moul JW. Rising prostate-spe- cific antigen after primary prostate cancer therapy. Nature clinical practice Urology. 2005;2(4):174-82. 73. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ES- TRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relaps- ing, Metastatic, and Castration-Re- sistant Prostate Cancer. Eur Urol. 2017;71(4):630-42. 74. Punnen S, Cooperberg MR, D’Amico AV, Karakiewicz PI, Moul JW, Scher HI, et al. Management of biochemical recur- rence after primary treatment of pros- tate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905-15. 75. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67(6):1009-16.